Ovarian carcinoma during pregnancy is a rare event that should be treated. In these cases, due to the lack of information available, doubts about the safety of mother and fetus are present. In this report, a 42-year-old woman who was diagnosed with a stage III ovarian carcinoma received six cycles of chemotherapy with carboplatin and paclitaxel from the 16th until 36th week of gestation. At 38 weeks, a normal male baby was born. There were no abnormalities during birth and during a 2-month follow-up period. This case adds to the available literature and supports the use of these chemotherapy agents during pregnancy, if the risk-benefit balance is appropriate.

Keywords:
Pregnancy, Chemotherapy, Ovary
1.
Zhao XY, Huang HF, Lian LJ, Lang JH: Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer 2006;16:8-15.
2.
Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R: Taxanes for ovarian cancer during pregnancy: a systematic review. Oncology 2012;83:234-238.
3.
Mir O, Berveiller P, Ropert S, Goffinet F, Goldwasser F: Use of platinum derivatives during pregnancy. Cancer 2008;113:3069-3074.
4.
Glantz JC: Reproductive toxicology of alkylating agents. Obstet Gynecol Surv 1994;49:709-715.
5.
Cardonick E, Iacobucci A: Use of chemotherapy during human pregnancy. Lancet Oncol 2004;5:283-291.
6.
Méndez LE, Mueller A, Salom E, González-Quintero VH: Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer. Obstet Gynecol 2003;102:1200-1202.
7.
Zagouri F, Sergentanis TN, Chrysikos D, Bartsch R: Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis. Obstet Gynecol 2013;121:337-343.
8.
Smith ER, Borowsky ME, Jain VD: Intraperitoneal chemotherapy in a pregnant woman with ovarian cancer. Obstet Gynecol 2013;122:481-483.
9.
Battelli C, Campo M, Buss MK, Awtrey CS, Konstantinopoulos PA: Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer. Chemotherapy 2013;59:251-259.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.